Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

Rhea-AI Summary

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced upcoming presentations at two major investor conferences. CEO and Co-founder Brian Sullivan will participate in:

- A fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 28, 2025, at 9:30 a.m. ET

- A fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 7:35 a.m. ET

Both presentations will be available via live webcast and can be accessed through the company's investor relations website, with recordings available shortly after the events.

MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit at 9:30 a.m. ET on Wednesday, May 28, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/cowen180/celc/1978947; and
• A fireside chat at the Jefferies Global Healthcare Conference at 7:35 a.m. ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff319/celc/1820072.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity 

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.

View source version of release on GlobeNewswire.com

Contacts: 
Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284

FAQ

When is Celcuity (CELC) presenting at the TD Cowen Oncology Innovation Summit?

Celcuity will present at the TD Cowen 6th Annual Oncology Innovation Summit on Wednesday, May 28, 2025, at 9:30 a.m. ET.

What time is Celcuity's presentation at the Jefferies Global Healthcare Conference?

Celcuity will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET.

Who will be presenting at the upcoming investor conferences for Celcuity (CELC)?

Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will be presenting at the conferences.

How can investors access Celcuity's conference presentations?

Investors can access the live webcasts through provided weblinks or through Celcuity's investor relations website at https://ir.celcuity.com/events-presentations/.